Table 4 Guidelines by various international organizations for COVID-19 vaccination in children
From: Dilemmas and options for COVID-19 vaccination in children
Organization | Type of vaccine | Developer(s) | Applicable age | Reference |
|---|---|---|---|---|
WHO | BNT162b2 (mRNA vaccine) | BioNTech + Fosun Pharma + Pfizer | a. ≥ 12 years: SAGE recommends two doses (30 µg, 0.3 ml each), 4–8 weeks apart given intramuscularly. b. 5 to 11 years: recommends two doses (10 µg, 0.2 ml each) given intramuscularly and provided 4–8 weeks apart. c. 6 months to 4 years: three doses (3 µg, 0.2 ml each): a schedule of two doses 3 weeks apart followed by a third dose at least 8 weeks after the second dose. | [79] |
mRNA-1273 (mRNA vaccine) | Moderna + NIAID | a. 12 to 17 years: two doses (100 µg, 0.5 ml each), given intramuscularly, 4 weeks apart. b. 6 to 11 years: two doses (50 µg in 0.25 ml each), 4 weeks apart. c. 6 months to 5 years: two doses (25 µg, 0.25 ml each), 4 weeks apart. | [80] | |
FDA | BNT162b2 (mRNA vaccine) | BioNTech + Fosun Pharma + Pfizer | a. 6 months to 4 years: children who have received two doses of the monovalent Pfizer-BioNTech COVID-19 vaccine can receive the bivalent Pfizer-BioNTech COVID-19 vaccine as the third dose. | [81] |
mRNA-1273 (mRNA vaccine) | Moderna + NIAID | a. 6 months to 5 years: children can receive the bivalent Moderna COVID-19 vaccine as a booster dose at least 2 months after completion of primary vaccination with the monovalent Moderna COVID-19 vaccine. | ||
CDC | Novavax (Protein subunit vaccine) | Novavax, Inc. | a. 12 to 17 years: Novavax is not authorized as a booster dose at this time and can only be used for primary series. | [82] |
BNT162b2 (mRNA vaccine) | BioNTech + Fosun Pharma + Pfizer | a. ≥ 12 years: recommends three doses, a schedule of two doses 3–8 weeks apart followed by a third dose at least 2 months after the second dose. b. 5 to 11 years: recommends three doses given intramuscularly and provided 3–8 weeks apart, children aged 5 years can only get a Pfizer-BioNTech booster, and children aged 6–11 years can get a Pfizer-BioNTech or Moderna booster at least 2 months after second dose or last booster. c. 6 months to 4 years: recommends three doses, a schedule of two doses 3 weeks apart followed by a third dose at least 8 weeks after the second dose. | ||
mRNA-1273 (mRNA vaccine) | Moderna + NIAID | a. 6 years above: a schedule of two doses, 4–8 weeks apart followed by a third dose at least 2 months after second primary series dose. b. 6 months to 5 years: 3 doses, 4 to 8 weeks apart. At least 2 months after second Moderna dose, children aged 6 months–4 years can only get a Moderna booster, and children aged 5 years can get a Pfizer-BioNTech or Moderna updated booster. | ||
EMA | Comirnaty (mRNA vaccine) | BioNTech + Fosun Pharma + Pfizer | a. ≥ 12 years: two doses of 30 micrograms each, 3 weeks apart. b. 5 to 11 years: two doses of 10 micrograms each, 3 weeks apart. c. 6 months to 4 years: three doses of 3 micrograms each, the first two doses are given three weeks apart, followed by a third dose given at least 8 weeks after the second dose. | [83] |
Spikevax (mRNA vaccine) | Moderna + NIAID | a. ≥ 12 years: two doses of 100 micrograms each, 28 days apart. b. 6 to 11 years: two doses of 50 micrograms each, 28 days apart. c. 6 months to 5 years: two doses of 25 micrograms each, 28 days apart. | [84] |